MedDataX Logo

Mometasone and Markers of Airway Inflammation

NCT00711165 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2008-07-08

No results posted yet for this study

Summary

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Conditions

  • Asthma

Interventions

DRUG

Placebo

2 puffs, qd

DRUG

Mometasone Furoate

400 mcg, qd for 8 weeks

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Thomas B Casale, MD · Creighton University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-04-30
Completion
2006-08-31

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711165 on ClinicalTrials.gov